Mayo Hospital, Pakistan Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04473261
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CHAIRMAN PEDIATRIC MEDICINE, MAYO HOSPITAL | Mayo Hospital, Pakistan

Active Ingredients

Drugs in Phase 4 Trials (1)

methylfolate (1 trial)

Drugs in Phase 2 Trials (4)

iodine (1 trial)

ivermectin (stromectol) (1 trial)

nigella sativa (1 trial)

zinc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5